• linkedin
  • Increase Font
  • Sharebar

    Suprachoroidal corticosteroid shows visual, anatomic improvements in DME eyes


    No adverse events

    There were no serious ocular or systemic adverse events and no unexpected or new safety signals.

    “Suprachoroidal CLS-TA has already completed other phase I and phase II trials, and there are multiple ongoing studies in phase II and phase III,” Dr. Wykoff said.

    Discussing limitations of the study, Dr. Wykoff noted the small sample size and short duration of the HULK trial, along with the variable disease management received by patients in the previously treated arms and different treatment exposures for the 2 arms during the 6-month trial.

    Charles C. Wykoff, MD, PhD

    e. [email protected]

    This article is based on a presentation given by Dr. Wykoff at the 2017 Retina Subspecialty Day prior to the 2017 American Academy of Ophthalmology meeting. Dr. Wykoff is a consultant to and receives grant support from Clearside Biomedical and from other companies that market or are developing treatments for DME. The HULK trial was supported by a grant from Clearside Biomedical.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';